The study, which used a mouse model undergoing partial hepatectomy (removal of two-thirds of the liver), revealed intricate molecular gradients and gene networks that guide liver regeneration. Key findings include the identification of the transcriptional cofactor TBL1XR1, which links inflammation with Wnt/β-catenin signaling, essential for promoting hepatocyte proliferation. These insights deepen our understanding of how gene networks dynamically adjust through intercellular communication to ensure liver regeneration, even under challenging conditions.
This high-resolution study also mapped the liver’s porto-central axis, detailing the spatial organization of liver cells and their roles in maintaining liver function. The combination of Stereo-seq with single-cell transcriptomic profiling allowed researchers to explore the liver’s zonation patterns and how different cell types, including hepatocytes and non-parenchymal cells, respond to liver injury.
PackGene played a vital role in this study by providing the AAV viral particles used to investigate gene function during liver regeneration. PackGene’s contribution enabled precise manipulation of liver cells, facilitating the researchers’ ability to dissect the molecular underpinnings of liver homeostasis and regeneration.
This spatiotemporal atlas sets the stage for future research aimed at understanding organ physiology and disease mechanisms at an unprecedented level of detail. Through innovations in single-cell and spatial transcriptomics, the study opens new avenues for exploring tissue regeneration and developing therapeutic strategies for liver diseases.
Source: Xu, J., Guo, P., Hao, S. et al. A spatiotemporal atlas of mouse liver homeostasis and regeneration. Nat Genet 56, 953–969 (2024). https://doi.org/10.1038/s41588-024-01709-7.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
AAV Gene Therapy Revolutionizes Treatment for LCA1, Improving Vision Significantly
Innovative AAV Gene Therapy Dramatically Restores Vision in LCA1 Researchers have made a significant breakthrough in treating Leber congenital amaurosis type 1 (LCA1), a severe inherited retinal disease that causes early childhood blindness, by using an innovative...
Cellular Origins & 3P Innovation Partner to Streamline Cell and Gene Therapy Manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
Voyager Therapeutics Expands Gene Therapy Portfolio with Novartis License for Next-Generation Capsid
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has entered into a licensing agreement with Novartis AG (NYSE: NVS) for a novel capsid developed using Voyager’s TRACER™ capsid discovery platform. This license will...
BridgeBio ends development of gene therapy for adrenal gland disorder
BridgeBio said Tuesday night it won’t move forward with a gene therapy for a group of genetic disorders that impair adrenal glands and cause disruptions in producing cortisol. The California biotech made the decision because Phase 1/2 data were “not yet...
Related Services
Plasmids GMP Services
AAV GMP Services
